To investigate whether ROCK–mTOR inhibitors have a general effect on human breast cancer cells, the reprogramming treatment of ROCK–mTOR inhibitors was used in another two breast cancer cell lines, HCC2157 and 4T1. The gene discussed is MTOR; the disease is breast carcinoma.